摘要:
The invention relates to inhibition of ornithine aminotransferase (OAT) for suppression of tumor cells proliferation. More particularly, the invention relates to methods of treatment of proliferative disorders by the selective inhibition of OAT, and further provides the use of OAT inhibitors, specifically, 5-amino-1,3-hexadienyl-carboxylic acid (Gabaculine), and Gabaculine analogue 8, for compositions and methods for the treatment of proliferative disorders such as hepatocellular carcinoma. The invention further provides methods and kits for the diagnosis of a pathologic proliferative disorder in a mammalian subject, based on determining the level of OAT expressed in a biological sample obtained from a subject.
摘要:
A gastrointestinal stimulation devices including a random stimulation delivery mechanism(s), configured to provide stimuli to a bodily tissue in a vicinity of the stimulation capsule, the provided random stimuli being characterized by a stimulation parameter, and a control circuitry in communication with said physical stimulation delivery mechanism, and configured to set and alter the stimulation parameter non-systematically, thereby altering the characterization of the stimuli provided to the bodily tissue. The algorithm may be patient tailored, and may have a learning machinery which responds to data being received from the patient.
摘要:
The present invention relates to immunomodulatory compositions comprising mammalian colostrum-derived immunoglobulin preparation and optionally further colostrums, milk or milk product component/s and any adjuvants for treating immune-related disorders. More specifically, the invention provides compositions comprising colostrum-derived anti-insulin immunoglobulin preparations for the treatment of Metabolic Syndrome. The invention further provides methods and uses of the immunomodulatory compositions for an active or passive immunization in a disease-antigen specific or non specific manner.
摘要:
The present disclosure provides systems, devices and methods for providing abdominal or any other organ stimulation for affecting a physiological change, wherein the stimulation parameters are continuously, semi continuously, or conditionally being updated based on measurements and inputs provided to a computer circuitry configured to facilitate machine learning capabilities.
摘要:
A device for detection of internal bleeding in a patient's body is provided. An optical interface for transmitting IR light through an area of a skin of a patient and to collect IR light from the area of the skin, is provided. In some embodiments the optical interface includes one or more delivery components and one or more collection components. The delivery component includes a plurality of first optical channels configured to transmit the IR light through a plurality of respective first sub-areas on the area of the skin, into an internal layer of the body. The collection component includes a plurality of second optical channels, configured to collect IR light from a plurality of respective second sub-areas on the area of the skin.
摘要:
A device for detection of internal bleeding in a patient's body is provided. An optical interface for transmitting IR light through an area of a skin of a patient and to collect IR light from the area of the skin, is provided. In some embodiments the optical interface includes one or more delivery components and one or more collection components. The delivery component includes a plurality of first optical channels configured to transmit the IR light through a plurality of respective first sub-areas on the area of the skin, into an internal layer of the body. The collection component includes a plurality of second optical channels, configured to collect IR light from a plurality of respective second sub-areas on the area of the skin.
摘要:
Methods of treating patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those also suffering front type II diabetes mellitus (T2DM), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.